Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals

American Journal of Respiratory and Critical Care Medicine

Volumn 161, Issue 6, 2000, Pages 1881-1886

  Lee, Elaine ^a   Robertson, Tracy ^a   Smith, Jacqueline ^a   Kilfeather, Stephen ^a  

^a UNIVERSITY OF SUNDERLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ARACHIDONATE 5 LIPOXYGENASE; FIBRONECTIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LEUKOTRIENE B4; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; N [3 (3 PHENOXYPHENYL)ALLYL]ACETOHYDROXAMIC ACID; PEPTIDOLEUKOTRIENE; POBILUKAST; SB 201146; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; ASTHMA; CELL SURVIVAL; CONTROLLED STUDY; ENZYME INHIBITION; EOSINOPHIL; EOSINOPHILIA; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE; MAST CELL; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION;

EID: 0034047709     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.161.6.9907054     Document Type: Article

References (28)

1. 1. Lofdahl, C. G., T. F. Reiss, J. A. Leff, E. Israel, M. J. Noonan, A. F. Finn, B. C. Seidenberg, T. Capizzi, S. Kundu, and P. Godard. 1999. Randomized, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. Br. Med. J. 319:87-90.
2. 2. Tamaoki, J., M. Kondo, N. Sakai, J. Nakata, H. Takemura, A. Nagai, T. Takizawa, and K. Konno. 1997. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. Am. J. Respir. Crit. Care Med. 155:1235-1240.
3. 3. Simon, H. U., and K. Blaser. 1995. Defective regulation of apoptosis -does it cause eosinophilia? Allergologie 18:48-51.
4. 4. Savill, J., and C. Haslett. 1995. Granulocyte clearance by apoptosis in the resolution of inflammation. Semin. Cell Biol. 6:385-393.
5. 5. Stankova, J., M. Rolapleszczynski, and C. M. Dubois. 1995. Granulocytemacrophage colony-stimulating factor increases 5-lipoxygenase gene-transcription and protein expression in human neutrophils. Blood 85: 3719-3726.
6. 4 receptor blockade and 5-lipoxygenase and 5-lipoxygenase activating protein inhibitor. Am. J. Respir. Crit. Care Med. 160: 2079-2085.
7. 7. Anwar, A. R. E., G. M. Walsh, O. Cromwell, A. B. Kay, and A. J. Wardlaw. 1994. Adhesion to fibronectin primes eosinophils via alpha(4)/ Beta(1) (VLA-4). Immunology 82:222-228.
8. 8. Walsh, G. M., and A. J. Wardlaw. 1997. Dexamethasone inhibits prolonged survival and autocrine granulocyte-macrophage colony-stimulating factor production by human eosinophils cultured on laminin or tissue fibronectin. J. Allergy Clin. Immunol. 100:208-215.
9. 9. Terada, N., H. Sagara, H. Yagita, K. Okumura, S. Makino, A. Konno, T. Yamashita, K. Togawa, and C. Ra. 1996. The effect of anti-VLA-4 monoclonal antibody on eosinophil accumulation and leukotriene production in nasal mucosa. Acta Otolaryngol. 116:883-887.
10. 10. Makino, S., and T. Fukuda. 1995. Eosinophils and allergy in asthma. Allergy Proc. 16:13-21.
11. 11. Park, C. S., Y. S. Choi, S. Y. Ki, S. H. Moon, S. W. Jeong, S. T. Uh, and Y. H. Kim. 1998. Granulocyte macrophage colony-stimulating factor is the main cytokine enhancing survival of eosinophils in asthmatic airways. Eur. Respir. J. 12:872-878.
12. 12. Sedgwick, J. B., S. F. Quan, W. J. Calhoun, and W. W. Busse. 1995. Effect of interleukin-5 and granulocyte-macrophage colony-stimulating factor on in-vitro eosinophil function: comparison with airway eosinophils. J. Allergy Clin. Immunol. 96:375-385.
13. 13. Roberge, C. J., S. R. Mccoll, B. Larochelle, and J. Gosselin. 1998. Granulocyte-macrophage colony-stimulating factor enhances EBV-induced synthesis of chemotactic factors in human neutrophils. J. Immunol. 160:2442-2448.
14. 14. Brock, T. G., R. W. Mcnish, M. J. Coffey, T. C. Ojo, S. M. Phare, and M. Peters Golden. 1996. Effect of granulocyte-macrophage colony-stimulating factor on eicosanoid production by mononuclear phagocytes. J. Immunol. 156:2522-2527.
15. 15. Krump, E., S. Boudreault, M. E. Surette, and P. Borgeat. 1997. Effect of GM-CSF on leukotriene B-4 synthesis in human neutrophils: facilitation of the priming effect by autologous plasma. Adv. Exp. Med. Biol. 400:583-587.
16. 16. Kita, H., T. Ohnishi, Y. Okubo, D. Weiler, J. S. Abrams, and G. J. Gleich. 1991. Granulocyte macrophage colony-stimulating factor and interleukin-3 release from human peripheral-blood eosinophils and neutrophils. J. Exp. Med. 174:745-748.
17. 17. Walsh, G. M., F. A. Symon, and A. J. Wardlaw. 1995. Human eosinophils preferentially survive on tissue fibronectin compared with plasma fibronectin. Clin. Exp. Allergy 25:1128-1136.
18. 18. Nagata, M., J. B. Sedgwick, and W. W. Busse. 1995. Differential-effects of granulocyte-macrophage colony-stimulating factor on eosinophil and neutrophil Superoxide anion generation. J. Immunol. 155:4948-4954.
19. 4 in the immune-system. Int. J. Immunopharmacol. 14:441-449.
20. 4. Biochem. Biophys. Res. Commun. 153:203-208.
21. 21. Macchia, L., M. Hamberg, M. Kumlin, J. H. Butterfield, and J. Z. Haeggstrom. 1995. Arachidonic-acid metabolism in the human mast-cell line hmc-1 - 5-lipoxygenase gene-expression and biosynthesis of thromboxane. Biochim. Biophys. Acta (Lipids Lipid Metab.) 1257:58-74.
22. 22. Hagan, J. B., H. Kita, and G. J. Gleich. 1998. Inhibition of interleukin-5 mediated eosinophil viability by fluticasone 17-propionate: comparison with other glucocorticoids. Clin. Exp. Allergy 28:999-1006.
23. 23. Anenden, V., E. Lee, G. Egemba, B. Kessel, M. Johnson, J. Costello, and S. A. Kilfeather. 1998. Salmeterol facilition of fluticasone-induced apoptosis in eosinophils of asthmatics pre- and post-antigen challenge. Eur. Respir. J. 12:157-157.
24. 24. Wenzel, S. E., J. B. Trudeau, D. A. Kaminsky, J. Cohn, R. J. Martin, and J. Y. Westcott. 1995. Effect of 5-lipoxygenase inhibition on broncho-constriction and airway inflammation in noeturnal asthma. Am. J. Respir. Crit. Care Med. 152:897-905.
25. 25. Malmstrom, K., G. RodriguezGomez, J. Guerra, C. Villaran, A. Pineiro, L. X. Wei, B. C. Seidenberg, and T. F. Reiss. 1999. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma - a randomized, controlled trial. Ann. Intern. Med. 130:487.
26. 26. Reiss, T. F., P. Chervinsky, R. J. Dockhorn, S. Shingo, B. Seidenberg, and T. B. Edwards. 1998. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Arch. Intern. Med. 158:1213-1220.
27. 27. Pizzichini, E., J. A. Leff, T. F. Reiss, L. Hendeles, L. P. Boulet, L. X. Wei, A. E. Efthimiadis, J. Zhang, and F. E. Hargreave. 1999. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur. Respir. J. 14:12-18.
28. 28. Kane, G. C., M. Pollice, C. J. Kim, J. Cohn, R. T. Dworski, J. J. Murray, J. R. Sheller, J. E. Fish, and S. P. Peters. 1996. A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J. Allergy Clin. Immunol. 97:646-654.